| Grayson Myers Loveless, NP | |
|
1100 Peachtree St Ne Ste 200, Atlanta, GA 30309-4829 | |
| (404) 445-5304 | |
| (404) 445-5173 |
| Full Name | Grayson Myers Loveless |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 3 Years |
| Location | 1100 Peachtree St Ne Ste 200, Atlanta, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396412458 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | RN265383 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Peachtree City Urgent Care, Inc | 3971655705 | 6 |
News Archive
"N60" might not be the first thing that comes to mind when people think of Alzheimer's disease, but thanks to researchers from the United States, South Korea and France, this might change. That's because these researchers have found that the N60 section of a protein called "RanBP9" might be the key that unlocks an entirely new class of Alzheimer's drugs, and with them, hope. In a research report published online in The FASEB Journal, these scientists describe how the N60 fragment of the RanBP9 protein increases the production of the amyloid beta protein, which is present in excessive amounts in the brains of people with Alzheimer's disease.
A recent neuroimaging study reveals that the ability to distinguish true from false in our daily lives involves two distinct processes. Previous research relied heavily on the premise that true and false statements are both processed in the left inferior frontal cortex.
The Cancer Prevention and Research Institute of Texas (CPRIT) today announced a strategic partnership agreement with the Swiss-based healthcare company Roche to accelerate the development of promising oncology-related cancer research projects in Texas.
The journal Health Affairs has a new study analyzing the effects of the 2006 Massachusetts health insurance law.
Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan-Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) Research Network.
› Verified 5 days ago
| Entity Name | Peachtree City Urgent Care, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336388636 PECOS PAC ID: 3971655705 Enrollment ID: O20090709000044 |
News Archive
"N60" might not be the first thing that comes to mind when people think of Alzheimer's disease, but thanks to researchers from the United States, South Korea and France, this might change. That's because these researchers have found that the N60 section of a protein called "RanBP9" might be the key that unlocks an entirely new class of Alzheimer's drugs, and with them, hope. In a research report published online in The FASEB Journal, these scientists describe how the N60 fragment of the RanBP9 protein increases the production of the amyloid beta protein, which is present in excessive amounts in the brains of people with Alzheimer's disease.
A recent neuroimaging study reveals that the ability to distinguish true from false in our daily lives involves two distinct processes. Previous research relied heavily on the premise that true and false statements are both processed in the left inferior frontal cortex.
The Cancer Prevention and Research Institute of Texas (CPRIT) today announced a strategic partnership agreement with the Swiss-based healthcare company Roche to accelerate the development of promising oncology-related cancer research projects in Texas.
The journal Health Affairs has a new study analyzing the effects of the 2006 Massachusetts health insurance law.
Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan-Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) Research Network.
› Verified 5 days ago
| Entity Name | Resurgia Health Solutions Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851702153 PECOS PAC ID: 2668699760 Enrollment ID: O20140813002730 |
News Archive
"N60" might not be the first thing that comes to mind when people think of Alzheimer's disease, but thanks to researchers from the United States, South Korea and France, this might change. That's because these researchers have found that the N60 section of a protein called "RanBP9" might be the key that unlocks an entirely new class of Alzheimer's drugs, and with them, hope. In a research report published online in The FASEB Journal, these scientists describe how the N60 fragment of the RanBP9 protein increases the production of the amyloid beta protein, which is present in excessive amounts in the brains of people with Alzheimer's disease.
A recent neuroimaging study reveals that the ability to distinguish true from false in our daily lives involves two distinct processes. Previous research relied heavily on the premise that true and false statements are both processed in the left inferior frontal cortex.
The Cancer Prevention and Research Institute of Texas (CPRIT) today announced a strategic partnership agreement with the Swiss-based healthcare company Roche to accelerate the development of promising oncology-related cancer research projects in Texas.
The journal Health Affairs has a new study analyzing the effects of the 2006 Massachusetts health insurance law.
Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan-Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) Research Network.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Grayson Myers Loveless, NP 213 Shadowood Ln, Peachtree City, GA 30269-2256 Ph: (817) 983-6117 | Grayson Myers Loveless, NP 1100 Peachtree St Ne Ste 200, Atlanta, GA 30309-4829 Ph: (404) 445-5304 |
News Archive
"N60" might not be the first thing that comes to mind when people think of Alzheimer's disease, but thanks to researchers from the United States, South Korea and France, this might change. That's because these researchers have found that the N60 section of a protein called "RanBP9" might be the key that unlocks an entirely new class of Alzheimer's drugs, and with them, hope. In a research report published online in The FASEB Journal, these scientists describe how the N60 fragment of the RanBP9 protein increases the production of the amyloid beta protein, which is present in excessive amounts in the brains of people with Alzheimer's disease.
A recent neuroimaging study reveals that the ability to distinguish true from false in our daily lives involves two distinct processes. Previous research relied heavily on the premise that true and false statements are both processed in the left inferior frontal cortex.
The Cancer Prevention and Research Institute of Texas (CPRIT) today announced a strategic partnership agreement with the Swiss-based healthcare company Roche to accelerate the development of promising oncology-related cancer research projects in Texas.
The journal Health Affairs has a new study analyzing the effects of the 2006 Massachusetts health insurance law.
Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan-Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) Research Network.
› Verified 5 days ago
Fidelia O Osinubi, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3885 Princeton Lakes Way, Suite 402, Atlanta, GA 30331 Phone: 404-349-0496 Fax: 404-349-6081 | |
Theresa R Jacobs, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 868 York Ave Sw, Atlanta, GA 30310 Phone: 404-752-1400 Fax: 404-758-0740 | |
David M Williams, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1046 Ridge Ave Sw, Atlanta, GA 30315 Phone: 404-688-1350 Fax: 404-564-6734 | |
Tony Serrano-padin, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1701 Hardee Ave. Sw, Bldg 125, Fort Mcpherson - Army Health Clinic, Atlanta, GA 30330 Phone: 404-464-0389 | |
Dr. Bhavi Patel Purohit, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 720 Westview Dr Sw, Atlanta, GA 30310 Phone: 404-756-1230 Fax: 404-752-8682 | |
Dr. Edmond Shih, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5461 Buford Hwy Ne, Atlanta, GA 30340 Phone: 770-457-5556 Fax: 770-457-7776 | |
Zahidul Islam Chowdhury, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 240 N Highland Ave Ne, Suite F, Atlanta, GA 30307 Phone: 404-658-9840 Fax: 404-658-9846 |